Claims
- 1. A process for converting a less active or slower to initiate catalyst system to a higher activity catalyst system, the process comprising contacting a protected N-heterocyclic carbene with a metathesis initiator and an olefin in the presence of energy.
- 2. The process of claim 1 wherein the protected N-heterocyclic carbene is of the formula NHC—X2—Y; wherein NHC is any N-heterocyclic carbene ligand and X2—Y is any moiety that is released in the presence of energy.
- 3. The process of claim 2 wherein the protected N-heterocyclic carbene is of the formula:
- 4. The process of claim 3 wherein the at least one substituent is substituted with one or more substituted or unsubstituted moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, and aryl.
- 5. The process of claim 4 wherein at least one moiety is substituted with one or more groups selected from the group consisting of halogen, a C1-C5 alkyl, C1-C5 alkoxy, and phenyl.
- 6. The process of claim 3 wherein at least one of the R6, R7, R8, R9, R10 and R11 substituent groups includes one or more functional groups selected from the group consisting of hydroxyl, thiol, alcohol, sulfonic acid, phosphine, thioether, ketone, aldehyde, ester, ether, amine, imine, amide, imide, imido, nitro, carboxylic acid, disulfide, carbonate, isocyanate, carbodiimide, carboalkoxy, carbamate, acetal, ketal, boronate, cyano, cyanohydrin, hydrazine, oxime, hydrazide, enamine, sulfone, sulfide, sulfenyl, and halogen.
- 7. The process of claim 3 wherein R7, R8, R9 and R10 are each independently selected from the group consisting of hydrogen, methyl, aralkyl, and aryl and R6 and R11 are each independently selected from the group consisting of substituted or unsubstituted C1-C10 alkyl, C1-C10 cycloalkyl, C2-C10 alkenyl, aralkyl, and aryl.
- 8. The process of claim 7 wherein R7, R8, R9 and R10 are each hydrogen and R6 and R11 substituents are each independently substituted or unsubstituted and are selected from the group consisting of phenyl, vinyl, methyl, isopropyl, tert-butyl, neopentyl, or benzyl.
- 9. The process of claim 8 wherein the substituent is substituted with one or more moieties selected from the group consisting of C1-C5 alkyl, C1-C5 alkoxy, phenyl, and a functional group.
- 10. The process of claim 8 wherein R6 and R11 are each independently substituted or unsubstituted aryl.
- 11. The process of claim 3 wherein at least two of R6, R7, R8, R9, R10 and R11 is linked to form an substituted or unsubstituted, saturated or unsaturated ring structure.
- 12. The process of claim 2 wherein the NHC—X2—Y is selected from the group consisting of 1,3-dimesityl-2-methoxy-imidazolidine, 1,3-dimesityl-2-(trichloromethyl)imidazolidine, 1,3-dimesityl-2-ethoxy-imidazolidine, 1,3-dimesityl-2-tert-butoxy-imidazolidine, 1,3-dimesityl-2-benzyloxy-imidazolidine, 1,3-diphenyl-2-(trichloromethyl)imidazolidine, 1,3-bis(3-chlorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-methylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-fluorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3-methylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-chlorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-bromophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-iodophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-methoxyphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-ethoxyphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-ethylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-nitrophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3,4-dimethylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3,5-dichlorophenyl)-2-(trichloromethyl) imidazolidine, 1,3-bis(3,5-dimethylphenyl )-2-(trichloromethyl imidazolidine, s-(4-chlorophenyl)-3-phenyl-2-(trichloromethyl)imidazolidine, 1,3-bis(4-fluorophenyl)-2-(trichloromethyl)imidazolidine, 1-(4- methoxyphenyl)-3-phenyl-2-(trichloromethyl imidazolidine, 2-(trichloromethyl)-1,3-bis(2,6-dimethyl-4-tert-butylphenyl)imidazolidine, 2-(trichloromethyl)-1,3-bis(2,6-diisopropylphenyl)imidazolidine, 1,3-dimesityl-2-dimethylamino-imidazolidine, 1-(1,3-dimesityl-2-imidazolidinyl)-piperidine, and, 4-(1,3-dimesityl-2-imidazolidinyl)-morpholine.
- 13. The process of claim 1 wherein the energy is selected from the group consisting of thermal energy, laser, electron beam radiation, gamma radiation, plasma, sound, ultra-violet, and microwave radiation.
- 14. The process of claim 1 wherein the olefin is cyclic or acyclic.
- 15. The process of claim 1 wherein the olefin contains more than one polymerizable double bond.
- 16. The process of claim 1 wherein the olefin is a monocyclic olefin or polycyclic olefin.
- 17. The process of claim 16 wherein the olefin is a substituted or unsubstituted monocyclic olefin and is selected from the group consisting of cyclopropene, cyclobutene, cyclopentene, methylcyclopentene, cycloheptene, cyclooctene, 5-acetoxycyclooctene, 5-hydroxycyclooctene, cyclooctadiene, cyclotetraene, cyclcodecene, and cyclododecene.
- 18. The process of claim 16 wherein the olefin is a polycyclic olefin and is selected from the group consisting of norbornene (bicyclo[2.2.1]hept-2-ene), 5-methyl-2-norbornene, ethylnorbornene, propylnorbornene, isopropylnorbornene, butylnorbornene, isobutylnorbornene, pentylnorbornene, hexylnorbornene, heptylnorbornene, octylnorbornene, decylnorbornene, dodecylnorbornene, octadecylnorbornene, p-tolylnorbornene, methylidene norbornene, phenylnorbornene, ethylidenenorbornene, vinylnorbornene, exo-dicyclopentadiene, endo-dicyclopentadiene, tetracyclododecene, methyltetracyclododecene, tetracyclododecadiene, dimethyltetracyclododecene, ethyltetracyclododecene, ethylidenyl tetracyclododecene, phenyltetracyclodecene, symmetrical and unsymmetrical trimers and tetramers of cyclopentadiene, 5,6-dimethylnorbornene, propenylnorbornene, 5,8-methylene-5a,8a-dihydrofluorene, cyclohexenylnorbornene, dimethanohexahydronaphthalene, endo,exo-5,6-dimethoxynorbornene, endo,endo-5,6-dimethoxynorbornene, 2,3-dimethoxynorbornadiene, 5,6-bis(chloromethyl)bicyclo[2.2.1]hept-2-ene, 5-tris(ethoxy)silylnorbornene, 2-dimethylsilylbicyclo[2.2.1]hepta-2,5-diene, 2,3-bistrifluoromethylbicyclo[2.2.1]hepta-2,5-diene, 5-fluoro-5-pentafluoroethyl-6-,6-bis(trifluoromethyl)bicyclo[2.2.1]hept-2-ene, 5,6-difluoro-5-heptatafluoroisopropyl-6-trifluoromethyl)bicyclo[2.2.1]hept-2-ene, 2,3,3,4,4,5,5,6-octafluorotricyclo[5.2.1.O]dec-8-ene, and 5-trifluoromethylbicyclo[2.2.1]hept-2-ene, 5,6-dimethyl-2-norbornene, 5-a-naphthyl-2-norbornene, 5,5-dimethyl-2-norbornene, 1,4,4a,9,9a,10-hexahydro-9,10[1′,2′]-benzeno-1,4-methanoanthracene. indanylnorbornene (i.e., 1,4,4,9-tetrahydro-1,4-methanofluorene, the reaction product of CPD and indene), 6,7,10,10-tetrahydro-7,10-methanofluoranthene (i.e., the reaction product of CPD with acenaphthalene), 1,4,4,9,9,10-hexahydro-9,10[1′,2′]-benzeno-1,4-methanoanthracene, endo,endo-5,6-dimethyl-2-norbornene, endo,exo-5,6-dimethyl-2-norbornene, exo,exo-5,6-dimethyl-2-norbornene, 1,4,4,5,6,9,10,13,14,14-decahydro-1,4-methanobenzocyclododecene (i.e., reaction product of CPD and 1,5,9-cyclododecatriene), 2,3,3,4,7,7-hexahydro-4,7-methano-1H-indene (i.e., reaction product of CPD and cyclopentene), 1,4,4,5,6,7,8,8-octahydro-1,4-methanonaphthalene (i.e., reaction product of CPD and cyclohexene), 1,4,4,5,6,7,8,9,10,10-decahydro-1,4-methanobenzocyclooctene, and 1,2,3,3,3,4,7,7,8,8,decahydro-4,7-methanocyclopent[a]indene.
- 19. The process of claim 1 wherein the metathesis initiator is any Ru or Os metal carbene metathesis catalyst.
- 20. The process of claim 19 wherein the metathesis catalyst is tetra-coordinated, penta-coordinated or hexa-coordinated.
- 21. The process of claim 19 wherein the catalyst possesses a metal center that is in the +2 oxidation state, has an electron count of 16, and is pentacoordinated.
- 22. The process of claim 21 wherein the catalyst is of the general formula
- 23. The process of claim 21 wherein the initiator is selected from the group consisting of
- 24. The process of claim 1 wherein the reaction occurs in the absence of a solvent.
- 25. The process of claim 1 wherein the olefin is a polymerizable monomer composition comprising more than one norbornene-type monomers wherein the norbornene-type monomers are the same or different.
- 26. A process for preparing a protected N-heterocyclic carbene, the process comprising contacting N-heterocyclic carbene salt with a base to form an N-heterocyclic carbene; and reacting the N-heterocyclic carbene with chloroform.
- 27. The process of claim 26 wherein the base is selected from the group consisting of lithium tert-butoxide, potassium tert-butoxide, sodium tert-butoxide, sodium hydride, lithium hydride, potassium hydride, potassium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, sodium hydroxide, lithium hydroxide, and potassium hydroxide.
- 28. The process of claim 26, wherein the process occurs in the absence of a solvent.
- 29. A process for converting a less active or slower to initiate catalyst system to a higher activity catalyst system, the process comprising contacting a protected N-heterocyclic carbene with a tetra-coordinated metathesis initiator and an olefin in the presence of energy.
- 30. The process of claim 29 wherein the olefin is substituted or unsubstituted norbornene.
- 31. The process of claim 29 wherein the olefin is substituted or unsubstituted dicyclopentadiene.
- 32. A process for converting a less active or slower to initiate catalyst system to a higher activity catalyst system, the process comprising contacting a protected N-heterocyclic carbene with a metathesis initiator and an acyclic olefin in the presence of energy.
- 33. A process for the ring-closing metathesis of one or more acylic olefins comprising contacting a protected N-heterocyclic carbene with a metathesis initiator and the one or more acylic olefins in the presence of energy.
- 34. The process of claim 33 wherein the protected N-heterocyclic carbene is of the formula NHC—X2—Y; wherein NHC is any N-heterocyclic carbene ligand and X2—Y is any moiety that is released in the presence of energy.
- 35. The process of claim 34 wherein the protected N-heterocyclic carbene is of the formula:
- 36. The process of claim 35 wherein the at least one substituent is substituted with one or more substituted or unsubstituted moieties selected from the group consisting of C1-C10 alkyl, C1-C10 alkoxy, and aryl.
- 37. The process of claim 35 wherein R7, R8, R9 and R10 are each independently selected from the group consisting of hydrogen, methyl, aralkyl, and aryl and R6 and R11 are each independently selected from the group consisting of substituted or unsubstituted C1-C10 alkyl, C1-C10 cycloalkyl, C2-C10 alkenyl, aralkyl, and aryl.
- 38. The process of claim 37 wherein R7, R8, R9 and R10 are each hydrogen and R6 and R11 substituents are each independently substituted or unsubstituted and are selected from the group consisting of phenyl, vinyl, methyl, isopropyl, tert-butyl, neopentyl, or benzyl.
- 39. The process of claim 35 wherein at least two of R6, R7, R8, R9, R10 and R11 is linked to form an substituted or unsubstituted, saturated or unsaturated ring structure.
- 40. The process of claim 34 wherein the NHC—X2—Y is selected from the group consisting of 1,3-dimesityl-2-methoxy-imidazolidine, 1,3-dimesityl-2-(trichloromethyl)imidazolidine, 1,3-dimesityl-2-ethoxy-imidazolidine, 1,3-dimesityl-2-tert-butoxy-imidazolidine, 1,3-dimesityl-2-benzyloxy-imidazolidine, 1,3-diphenyl-2-(trichloromethyl)imidazolidine, 1,3-bis(3-chlorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-methylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-fluorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3-methylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-chlorophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-bromophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-iodophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-methoxyphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-ethoxyphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-ethylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(4-nitrophenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3,4-dimethylphenyl)-2-(trichloromethyl)imidazolidine, 1,3-bis(3,5-dichlorophenyl)-2-(trichloromethyl) imidazolidine, 1,3-bis(3,5-dimethylphenyl)-2-(trichloromethyl imidazolidine, 1-(4-chlorophenyl)-3-phenyl-2-(trichloromethyl) imidazolidine, 1,3-bis(4-fluorophenyl)-2-(trichloromethyl)imidazolidine, 1-(4-methoxyphenyl)-3-phenyl-2-(trichloromethyl imidazolidine, 2-(trichloromethyl)-1,3-bis(2,6-dimethyl-4-tert-butylphenyl)imidazolidine, 2-(trichloromethyl)-1,3-bis(2,6-diisopropylphenyl)imidazolidine, 1,3-dimesityl-2-dimethylamino-imidazolidine, 1-(1,3-dimesityl-2-imidazolidinyl)-piperidine, and, 4-(1,3-dimesityl-2-imidazolidinyl)-morpholine.
- 41. The process of claim 33 wherein the energy is selected from the group consisting of of thermal energy, laser, electron beam radiation, gamma radiation, plasma, sound, ultra-violet, and microwave radiation.
- 42. The process of claim 33 wherein the olefin contains more than one polymerizable double bond.
- 43. The process of claim 33 wherein the metathesis initiator is any Ru or Os metal carbene metathesis catalyst.
- 44. The process of claim 43 wherein the metathesis catalyst is tetra-coordinated, penta-coordinated or hexa-coordinated.
- 45. The process of claim 43 wherein the initiator possesses a metal center that is in the +2 oxidation state, has an electron count of 16, and is pentacoordinated.
- 46. The process of claim 45 wherein the initiator is of the general formula
- 47. The process of claim 45 wherein the initiator is selected from the group consisting of
- 48. The process of claim 33 wherein the reaction occurs in the absence of a solvent.
- 49. A process for forming a metal carbene metathesis catalyst containing an N-heterocyclic carbene ligand, the process comprising contacting a protected N-heterocyclic carbene with a Ru or Os source and a substituted or unsubstituted acetylene and an olefin in the presence of energy.
- 50. The process of claim 49 wherein the process further comprises contacting the metal carbene metathesis catalyst with a substituted or unsubstituted acyclic olefin.
- 51. A process for forming a metal carbene metathesis catalyst containing an N-heterocyclic carbene ligand, the process comprising contacting a protected N-heterocyclic carbene with a Ru or Os source and a substituted or unsubstituted aryl and an olefin in the presence of energy.
- 52. A process for the acyclic diene metathesis of one or more acyclic dienes, the process comprising contacting a protected N-heterocyclic carbene with a metathesis initiator and the one or more acyclic dienes in the presence of energy.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/278,311, filed Mar. 23, 2001 and entitled High Activity Ru Alkylidene & Vinylidene Derivatives Suitable for Olefin Metathesis Generated using a Thermally Deprotectable N-Heterocyclic Carbene; U.S. Provisional Patent Application No. 60/288,680, filed May 3, 2001 and entitled High Activity Group 8 Alkylidene and Vinylidene Derivatives Suitable for Olefin Metathesis Generated Using a Thermally Activated N-Heterocyclic Carbene (NHC) Precursor”; and U.S. Provisional Patent Application No. ______, filed Mar. 1, 2002 and entitled “Polymer Processing Methods and Techniques Using Pentacoordinated or Hexacoordinated Ruthenium or Osmium Metathesis Catalysts”, the contents of each of which are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60278311 |
Mar 2001 |
US |
|
60288680 |
May 2001 |
US |